<DOC>
	<DOCNO>NCT01079351</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability steady-state pharmacokinetics intravenous ( IV ) Carbamazepine ( CBZ ) infusion relative orally administer CBZ adult patient epilepsy .</brief_summary>
	<brief_title>A Study Pharmacokinetics ( PK ) Safety IV Carbamazepine Relative Oral Carbamazepine Adults With Epilepsy</brief_title>
	<detailed_description>This phase 1 , multicenter , sequential , open-label study design assess safety , tolerability pharmacokinetics IV CBZ relative orally administer CBZ adult subject epilepsy . The study design use increase dose/treatment escalation cohort paradigm wherein subject enrol cohort base total daily dose ( TDD ) oral CBZ calculate creatinine clearance ( CLcr ; calculate Cockroft-Gault equation ) Day -28 . The purpose increase dose/treatment escalation cohort design provide mean independent data monitoring committee ( IDMC ) ass safety prior enrol subsequent cohort ; data summarize infusion time , renal function dose . The initial subject enrol normal renal function ( CLcr &gt; = 80 mL/min ) stable oral dose CBZ 400 mg/day 800 mg/day . Subsequent Dosing Cohorts enrol subject higher dose oral CBZ allow subject renal impairment enrol .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Patient must diagnose approve epilepsy indication CBZ include : Partial seizure complex symptomatology ( psychomotor , temporal lobe ) ; Generalized tonic clonic seizure ( grand mal ) ; Mixed seizure pattern include one ; Other partial generalize seizure . Patient must receive stable dose oral CBZ ( tablet capsule formulation ) minimum 14 day prior Day 28 . Patient must receive constant dose concomitant medication / device ( include AEDs , Vagal Nerve Stimulator ( VNS ) , OTC medication , herbal supplement ) may interfere metabolism CBZ minimum 14 day prior Day 28 . No change baseline AEDs expect treatment period . The patient must able comply maintain accurate epilepsy medication dose diary seizure diary . If female : Patient childbearing potential . If childbearing potential : Must negative serum pregnancy test Day 28 negative serum pregnancy test Day 1 ; Must comply method birth control acceptable investigator ( exception hormone base contraceptive contraindicate use CBZ ) . Patient take daily oral dose CBZ great 2000 mg per day . Patient treat hormone base therapy birth control . Patient QTc interval value great 450 msec . Patient screen ALT , AST bilirubin &gt; 3 time upper limit normal . Patients CLCR &lt; 30 mL/min renal disorder ( i.e . nephrotic syndrome , patient hemodialysis peritoneal dialysis consider peritoneal hemodialysis ) . Patient receive oral CBZ absence seizure . Patient episode status epilepticus within 30 day screen . Patient history severe serious adverse reaction CBZ ( e.g . aplastic anemia , agranulocytosis ) . Patient diagnose narrow angle glaucoma . Patient weigh less 50 kg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Intravenous Carbamazepine</keyword>
	<keyword>Oral Carbamazepine</keyword>
</DOC>